TSMC reported Q2 2026 net income of T$706.56 billion (approximately US$21.98 billion), a record high that exceeded analyst consensus forecasts of T$632.6 billion and surged approximately 77% year-on-year (CNBC, Reuters). Quarterly profit rose over 23% from the prior quarter. Net revenue reached NT$1,270.38 billion, up 12.0% sequentially (TSMC Management Report). The earnings conference call took place on July 13, 2026.

TSMC guided Q3 2026 revenue with a lower bound of $44.6 billion (CNBC). Alongside the results, the company announced plans to invest an additional $100 billion in the United States (Reuters). The capex commitment comes amid mounting pressure on semiconductor supply chains to localize advanced-node manufacturing capacity on U.S. soil.

The magnitude of the earnings beat — T$74 billion above consensus — is itself a signal. When a foundry of TSMC's scale posts a double-digit sequential revenue increase on top of a 77% YoY profit surge, the primary driver is wafer pricing power at leading-edge nodes, not unit volume alone. The Q3 revenue floor of $44.6 billion, if achieved, would represent continued sequential acceleration from Q1's US$35.90 billion in revenue (which was itself up 40.6% year-over-year) (TSMC press release). January–February 2026 revenue had already totaled NT$718.91 billion, up 29.9% from the same period in 2025 (TSMC press release).

Chip Stocks Sell Off Despite the Print

The record results did not translate into sector-wide strength. On July 16, 2026, the PHLX Semiconductor Index (SOX) fell 5%, and the Nasdaq Composite slipped approximately 1% (WSJ). Sandisk, Western Digital, and Marvell were among the biggest Nasdaq losers on the session. The selloff was global in scope: chip stocks declined across equity markets from Asia to the U.S., with AI-related technology names falling broadly (Reuters).

The weakness extended a pattern from the prior session. On July 15, 2026, Micron Technology shares declined 8%, Lam Research dropped 3%, and AMD also fell (CNBC). The sell-down occurred even as SK Hynix shares surged nearly 13% the same day, driven by AI optimism and tracking U.S. stock gains (Reuters). South Korean chip equipment maker Hanmi gained about 25% in early trade that session.

The divergence — a foundry reporting record profit while the semiconductor complex sells off — points to positioning and expectations rather than fundamentals. The AI trade narrative has cycled through multiple phases over recent weeks. The Wall Street Journal described it in a May 31 article as powering stocks to a "historic rally" (WSJ). By July 7, the Journal reported a "U.S. Stocks Retreat on Worries About AI Trade," citing a sharp selloff in chip stocks (WSJ). Two days later, on July 9, investors revived the trade, sparking a tech rally (WSJ). SK Hynix's U.S. ADR debut on July 10, priced at $149 and opening 14% higher, was characterized by the Journal as the AI trade passing "another test" (Reuters, WSJ). Yet by July 13, another selloff materialized (WSJ).

For market participants, the pattern is now familiar enough to price in. When consensus estimates are beaten by T$74 billion and the sector still sells off 5%, the question shifts from earnings fundamentals to whether the AI capex cycle's durability is being re-priced. The $100 billion U.S. investment pledge, layered on top of existing commitments, raises the capital intensity of the entire AI infrastructure build-out — and with it, the break-even utilization rates that foundries and their suppliers need to sustain. TSMC's Q3 guidance floor of $44.6 billion in revenue is the number to watch: any sequential deceleration from there would narrow the gap between elevated capex and revenue growth, and markets are clearly already wrestling with that risk.

UnitedHealth Group Raises 2026 Guidance

UnitedHealth Group reported Q2 2026 revenues of $112.0 billion, earnings from operations of $8.0 billion, and earnings of $6.04 per share, raising its full-year 2026 guidance alongside the results (UnitedHealth Group). The release was issued before the market open on July 16. UNH traded at $423.88 at midday.

UnitedHealth's results provide a counterweight to the tech-driven narrative. A $112 billion quarterly revenue base with an operating margin of roughly 7.1% and a raised full-year outlook is a fundamentally different earnings profile from the semiconductor cycle. The healthcare conglomerate's ability to lift guidance — in a period when tech investors are de-risking the AI trade — reflects a divergence in earnings visibility across sectors that is worth noting, though any causal link between the two would be speculative.